EBGLYSS durable efficacy has taken center stage in the dermatology world as Eli Lilly and Company (NYSE: LLY) recently announced groundbreaking four-year data from its [Read More…]
Topline results from the Phase 3 VALOR study demonstrate that the Lyme disease vaccine candidate (PF-07307405) is safe, well-tolerated, and effective for adults and children.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
Novartis unveils over 20 abstracts at AAD 2026, highlighting Rhapsido’s (remibrutinib) early intervention in CSU and Cosentyx’s (secukinumab) sustained performance in complex skin diseases.
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data from the ARTEMIS-001 trial, this B7-H3-targeted antibody-drug conjugate aims to transform the prognosis for patients with extensive-stage disease, who currently face a median survival of just 8 months. This marks the sixth major global regulatory designation for risvutatug rezetecan, signaling its critical role in the future of oncology.
Pfizer’s landmark Phase 3 TALAPRO-3 trial confirms that the Talzenna Xtandi rPFS mCSPC combination markedly exceeds its pre-specified efficacy target — advancing PARP inhibition earlier into the prostate cancer treatment course than ever before proven in a randomised study.
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
Atirmociclib Phase 2Â data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically [Read More…]
EBGLYSS (lebrikizumab) achieves groundbreaking Phase 3 results in children 6 months-18 years with moderate-to-severe atopic dermatitis. 63% achieved EASI-75 skin improvement. Learn about this selective IL-13 inhibitor breakthrough.
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
